Bromocriptine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Changed protection level for "Bromocriptine" ([Edit=Allow only autoconfirmed users] (expires 15:04, 18 June 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 15:04, 18 June 2014 (UTC))))
No edit summary
Line 35: Line 35:


There appear to be some connections between [[insulin insensitivity]] and [[dopamine]]. A company called Veroscience <ref>http://www.veroscience.com/research.html</ref> is using bromocriptine to treat [[diabetes]] and [[obesity]], and their website postulates a connection between neurotransmitters and seasonal variation in [[insulin]] sensitivity among vetebrate animals.<ref>Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999 Oct;8(10):1683-1707.</ref> There are also some connections between temperature and dopamine and serotonin production.<ref>http://sulcus.berkeley.edu/mcb/165_001/papers/manuscripts/_281.html</ref> In addition, new research indicates that patients with [[diabetes]] are more likely to develop [[parkinson's disease]], which is characterized by a dopamine deficiency in the brain.
There appear to be some connections between [[insulin insensitivity]] and [[dopamine]]. A company called Veroscience <ref>http://www.veroscience.com/research.html</ref> is using bromocriptine to treat [[diabetes]] and [[obesity]], and their website postulates a connection between neurotransmitters and seasonal variation in [[insulin]] sensitivity among vetebrate animals.<ref>Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999 Oct;8(10):1683-1707.</ref> There are also some connections between temperature and dopamine and serotonin production.<ref>http://sulcus.berkeley.edu/mcb/165_001/papers/manuscripts/_281.html</ref> In addition, new research indicates that patients with [[diabetes]] are more likely to develop [[parkinson's disease]], which is characterized by a dopamine deficiency in the brain.
===Pill Images===
{{TempDrugImages}}
{{PillImage|fileName=Parlodel_NDC_00780017.jpg|drugName=Parlodel|NDC=00780017|drugAuthor=Novartis Pharmaceuticals Corporation|ingredients=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|pillImprint=PARLODEL;2;12|dosageValue=2.5|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=8|pillScore=2}}
{{PillImage|fileName=Parlodel_NDC_00780102.jpg|drugName=Parlodel|NDC=00780102|drugAuthor=Novartis Pharmaceuticals Corporation|ingredients=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|pillImprint=PARLODEL;5;mg;S|dosageValue=5|dosageUnit=mg|pillColor=Brown|pillShape=Capsule|pillSize=16|pillScore=1}}
{{PillImage|fileName=Bromocriptine_Mesylate_NDC_03782042.jpg|drugName=Bromocriptine Mesylate|NDC=03782042|drugAuthor=Mylan Pharmaceuticals Inc.|ingredients=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|pillImprint=M;42|dosageValue=2.5|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=7|pillScore=2}}
{{PillImage|fileName=Bromocriptine_Mesylate_NDC_03787096.jpg|drugName=Bromocriptine Mesylate|NDC=03787096|drugAuthor=Mylan Pharmaceuticals Inc.|ingredients=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|pillImprint=MYLAN;7096|dosageValue=5|dosageUnit=mg|pillColor=Brown;White|pillShape=Capsule|pillSize=14|pillScore=1}}
{{PillImage|fileName=Bromocriptine_mesylate_NDC_05740106.jpg|drugName=Bromocriptine mesylate|NDC=05740106|drugAuthor=Paddock Laboratories, Inc.|ingredients=Bromocriptine mesylate[Bromocriptine]|pillImprint=PAD;0106|dosageValue=2.5|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=8|pillScore=2}}
{{PillImage|fileName=CYCLOSET_NDC_680120258.jpg|drugName=CYCLOSET|NDC=680120258|drugAuthor=Santarus, Inc.|ingredients=bromocriptine mesylate[bromocriptine]|pillImprint=C;9|dosageValue=0.8|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=6|pillScore=1}}


==Structure==
==Structure==

Revision as of 22:47, 16 July 2014

Bromocriptine
Clinical data
Pregnancy
category
  • A
Routes of
administration		oral
ATC code
Legal status
Legal status
  • ?
Pharmacokinetic data
Bioavailability28% of oral dose absorbed
Metabolism?
Elimination half-life12-14 hours
Excretion85% bile (faeces)
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC32H40BrN5O5
Molar mass654.595

WikiDoc Resources for Bromocriptine

Articles

Most recent articles on Bromocriptine

Most cited articles on Bromocriptine

Review articles on Bromocriptine

Articles on Bromocriptine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bromocriptine

Images of Bromocriptine

Photos of Bromocriptine

Podcasts & MP3s on Bromocriptine

Videos on Bromocriptine

Evidence Based Medicine

Cochrane Collaboration on Bromocriptine

Bandolier on Bromocriptine

TRIP on Bromocriptine

Clinical Trials

Ongoing Trials on Bromocriptine at Clinical Trials.gov

Trial results on Bromocriptine

Clinical Trials on Bromocriptine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bromocriptine

NICE Guidance on Bromocriptine

NHS PRODIGY Guidance

FDA on Bromocriptine

CDC on Bromocriptine

Books

Books on Bromocriptine

News

Bromocriptine in the news

Be alerted to news on Bromocriptine

News trends on Bromocriptine

Commentary

Blogs on Bromocriptine

Definitions

Definitions of Bromocriptine

Patient Resources / Community

Patient resources on Bromocriptine

Discussion groups on Bromocriptine

Patient Handouts on Bromocriptine

Directions to Hospitals Treating Bromocriptine

Risk calculators and risk factors for Bromocriptine

Healthcare Provider Resources

Symptoms of Bromocriptine

Causes & Risk Factors for Bromocriptine

Diagnostic studies for Bromocriptine

Treatment of Bromocriptine

Continuing Medical Education (CME)

CME Programs on Bromocriptine

International

Bromocriptine en Espanol

Bromocriptine en Francais

Business

Bromocriptine in the Marketplace

Patents on Bromocriptine

Experimental / Informatics

List of terms related to Bromocriptine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bromocriptine (brand names include Parlodel), an ergoline derivative, is a dopamine agonist that is used in the treatment of pituitary tumors and Parkinson's disease.

Uses

Amenorrhea, female infertility, galactorrhea, hypogonadism, and acromegaly may all be caused by pituitary problems, such as hyperprolactinaemia, and therefore, these problems may be treated by this drug.

It has also used in some countries to prevent lactation following childbirth if the mother does not wish to breastfeed; one of dopamine's effects on the pituitary is as an antagonist of prolactin production by lactotrophs. However, the FDA removed this indication in 1995, because of concerns with respect to an increased risk of heart attack, seizure and stroke.

Because of prolactin's role in stimulating proliferation of the T-lymphocytes of the immune system, bromocriptine has also been used to suppress the immune system in organ transplant patients.[1]

Since bromocryptine acts as a dopamine agonist, it has potential use in treating cocaine addiction, since the addictive effects of cocaine are caused by it blocking dopamine reuptake. Although it has negligible subjective effects when administered alone, studies show it has the potential to significantly ease the cocaine withdrawal syndrome.[2][3]

There appear to be some connections between insulin insensitivity and dopamine. A company called Veroscience [4] is using bromocriptine to treat diabetes and obesity, and their website postulates a connection between neurotransmitters and seasonal variation in insulin sensitivity among vetebrate animals.[5] There are also some connections between temperature and dopamine and serotonin production.[6] In addition, new research indicates that patients with diabetes are more likely to develop parkinson's disease, which is characterized by a dopamine deficiency in the brain.

Pill Images

{{#ask: Page Name::Bromocriptine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }} {{#subobject: 

 |Page Name=Bromocriptine
 |Pill Name=Parlodel_NDC_00780017.jpg
 |Drug Name=Parlodel
 |Pill Ingred=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|+sep=;
 |Pill Imprint=PARLODEL;2;12
 |Pill Dosage=2.5 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=8
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Novartis Pharmaceuticals Corporation
 |NDC=00780017

}}

{{#subobject: 

 |Page Name=Bromocriptine
 |Pill Name=Parlodel_NDC_00780102.jpg
 |Drug Name=Parlodel
 |Pill Ingred=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|+sep=;
 |Pill Imprint=PARLODEL;5;mg;S
 |Pill Dosage=5 mg
 |Pill Color=Brown|+sep=;
 |Pill Shape=Capsule
 |Pill Size (mm)=16
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=Novartis Pharmaceuticals Corporation
 |NDC=00780102

}}

{{#subobject: 

 |Page Name=Bromocriptine
 |Pill Name=Bromocriptine_Mesylate_NDC_03782042.jpg
 |Drug Name=Bromocriptine Mesylate
 |Pill Ingred=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|+sep=;
 |Pill Imprint=M;42
 |Pill Dosage=2.5 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=7
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Mylan Pharmaceuticals Inc.
 |NDC=03782042

}}

{{#subobject: 

 |Page Name=Bromocriptine
 |Pill Name=Bromocriptine_Mesylate_NDC_03787096.jpg
 |Drug Name=Bromocriptine Mesylate
 |Pill Ingred=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|+sep=;
 |Pill Imprint=MYLAN;7096
 |Pill Dosage=5 mg
 |Pill Color=Brown;White|+sep=;
 |Pill Shape=Capsule
 |Pill Size (mm)=14
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=Mylan Pharmaceuticals Inc.
 |NDC=03787096

}}

{{#subobject: 

 |Page Name=Bromocriptine
 |Pill Name=Bromocriptine_mesylate_NDC_05740106.jpg
 |Drug Name=Bromocriptine mesylate
 |Pill Ingred=Bromocriptine mesylate[Bromocriptine]|+sep=;
 |Pill Imprint=PAD;0106
 |Pill Dosage=2.5 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=8
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Paddock Laboratories, Inc.
 |NDC=05740106

}}

{{#subobject: 

 |Page Name=Bromocriptine
 |Pill Name=CYCLOSET_NDC_680120258.jpg
 |Drug Name=CYCLOSET
 |Pill Ingred=bromocriptine mesylate[bromocriptine]|+sep=;
 |Pill Imprint=C;9
 |Pill Dosage=0.8 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=6
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=Santarus, Inc.
 |NDC=680120258

}}


Structure

Like all ergopeptides, bromocriptine is a cyclol; two peptide groups of its tripeptide moiety (shown in black at the upper left of the Figure) are crosslinked, forming the >N-C(OH)< juncture between the two lactam rings.

See also

Cabergoline


References

  1. ↑ Clodi M, Kotzmann H, Riedl M, Schmidt A, Barnas U, Muhlbacher F, Mustafa G, Horl WH, Waldhausl W, Mayer G, Luger A., 1997. The long-acting dopamine agonist bromocriptine mesylate as additive immunosuppressive drug after kidney transplantation. Nephrol Dial Transplant. 1997 Apr;12(4):748-52.
  2. ↑ Campbell A, Baldessarini RJ, Cremens C, Teicher MH, Marsh E, Kula NS, 1989. Bromocriptine antagonizes behavioral effects of cocaine in the rat. Neuropsychopharmacology 1989 Sep; 2(3):209-24.
  3. ↑ KL Preston, JT Sullivan, EC Strain and GE Bigelow, 1992. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther. 1992 Jul;262(1):279-91.
  4. ↑ http://www.veroscience.com/research.html
  5. ↑ Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999 Oct;8(10):1683-1707.
  6. ↑ http://sulcus.berkeley.edu/mcb/165_001/papers/manuscripts/_281.html


Template:Ergolines Template:Dopamine agonists

de:Bromocriptin hu:Bromokriptin it:Bromocriptina sv:Bromokriptin

Retrieved from "https://www.wikidoc.org/index.php?title=Bromocriptine&oldid=994717"